Catherine M. Bollard

Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Immunotherapy for Epstein-Barr virus-associated cancers in children.

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.

Adoptive immunotherapy for posttransplantation viral infections.

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Adenoviral infections in hematopoietic stem cell transplantation.

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.

Adoptive immunotherapy for Hodgkin's lymphoma.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.

Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells.

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.

Novel cord blood transplant therapies.

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Aggressive peripheral CD70-positive t-cell lymphoma associated with severe chronic active EBV infection.

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγnull (NSG) mice.

Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma.

Good T cells for bad B cells.